Pfizer: to co-promote Exact Sciences' colorectal cancer test
(CercleFinance.com) - Exact Sciences said US pharma giant Pfizer has agreed to co-promote its FDA-approved non-invasive stool DNA screening test for colorectal cancer.
Under the terms of the agreement, whose financial terms were not specified, Pfizer will jointly promote Cologuard as from the fourth quarter of 2018.
While recognised as the most preventable form of cancer, colorectal cancer remains the second leading cause of cancer death in the US, with over 50,000 deaths each year.
The news prompted Exact Sciences shares to jump almost 20% in pre-market trading today.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
Under the terms of the agreement, whose financial terms were not specified, Pfizer will jointly promote Cologuard as from the fourth quarter of 2018.
While recognised as the most preventable form of cancer, colorectal cancer remains the second leading cause of cancer death in the US, with over 50,000 deaths each year.
The news prompted Exact Sciences shares to jump almost 20% in pre-market trading today.
Copyright (c) 2018 CercleFinance.com. All rights reserved.